Bernard Coulie Pliant Therapeutics, Inc. (PLRX) insider trading activity

Bernard Coulie is President and CEO of PLIANT THERAPEUTICS, INC.. Currently has a direct ownership of 482,936 shares of PLRX, which is worth approximately $6.38 Million. The most recent transaction as insider was on Jul 10, 2024, when has been sold 38,710 shares (Common Stock) at a price of $11.56 per share, resulting in proceeds of $447,487. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 483K

0% 3M change

41.17% 12M change

Total Value Held $6.38 Million

Bernard Coulie Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 10 2024	SELL Open market or private sale	$447,487 $11.56 p/Share	38,710 Reduced 7.42%	482,936 Common Stock
Jul 09 2024	BUY Grant, award, or other acquisition	-	75,625 Added 12.66%	521,646 Common Stock
Jan 23 2024	BUY Grant, award, or other acquisition	-	128,150 Added 22.38%	444,532 Common Stock
Jan 17 2024	SELL Open market or private sale	$443,172 $17.23 p/Share	25,721 Reduced 7.52%	316,382 Common Stock
Jul 17 2023	SELL Open market or private sale	$1,263,401 $18.01 p/Share	70,150 Reduced 17.02%	342,103 Common Stock
Jul 14 2023	BUY Grant, award, or other acquisition	-	137,500 Added 25.01%	412,253 Common Stock
Mar 30 2023	SELL Open market or private sale	$937,190 $26.52 p/Share	35,339 Reduced 11.4%	274,753 Common Stock
Mar 29 2023	BUY Grant, award, or other acquisition	-	68,749 Added 18.15%	310,092 Common Stock
Feb 03 2023	SELL Open market or private sale	$505,800 $33.72 p/Share	15,000 Reduced 5.88%	240,112 Common Stock
Feb 03 2023	BUY Exercise of conversion of derivative security	$93,300 $6.22 p/Share	15,000 Added 5.55%	255,112 Common Stock
Feb 02 2023	SELL Open market or private sale	$518,249 $34.55 p/Share	15,000 Reduced 5.88%	240,112 Common Stock
Feb 02 2023	BUY Exercise of conversion of derivative security	$93,300 $6.22 p/Share	15,000 Added 5.55%	255,112 Common Stock
Feb 01 2023	SELL Open market or private sale	$522,450 $34.83 p/Share	15,000 Reduced 5.88%	240,112 Common Stock
Feb 01 2023	BUY Exercise of conversion of derivative security	$93,300 $6.22 p/Share	15,000 Added 5.55%	255,112 Common Stock
Jan 31 2023	SELL Open market or private sale	$523,800 $34.92 p/Share	15,000 Reduced 5.88%	240,112 Common Stock
Jan 31 2023	BUY Exercise of conversion of derivative security	$62,250 $4.15 p/Share	15,000 Added 5.55%	255,112 Common Stock
Jan 30 2023	SELL Open market or private sale	$514,800 $34.32 p/Share	15,000 Reduced 5.88%	240,112 Common Stock
Jan 30 2023	BUY Exercise of conversion of derivative security	$31,200 $2.08 p/Share	15,000 Added 5.55%	255,112 Common Stock
Jan 27 2023	SELL Open market or private sale	$536,100 $35.74 p/Share	15,000 Reduced 5.88%	240,112 Common Stock
Jan 27 2023	BUY Exercise of conversion of derivative security	$31,200 $2.08 p/Share	15,000 Added 5.55%	255,112 Common Stock
Jan 26 2023	SELL Open market or private sale	$529,350 $35.29 p/Share	15,000 Reduced 5.88%	240,112 Common Stock
Jan 26 2023	BUY Exercise of conversion of derivative security	$31,200 $2.08 p/Share	15,000 Added 5.55%	255,112 Common Stock
Jan 25 2023	SELL Open market or private sale	$492,750 $32.85 p/Share	15,000 Reduced 13.79%	93,812 Common Stock
Jan 25 2023	BUY Grant, award, or other acquisition	-	146,300 Added 37.86%	240,112 Common Stock
Jan 25 2023	BUY Exercise of conversion of derivative security	$31,200 $2.08 p/Share	15,000 Added 12.12%	108,812 Common Stock

Also insider at

SQZ

SQZ Biotechnologies Co Healthcare

Director

Bernard Coulie

President and CEO

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells PLRX shares.

Notify only if

Value

Insider Trading

Get notified when an Pliant Therapeutics, Inc. insider buys or sells PLRX shares.

Notify only if

Operation

Value

Type

News

Receive news related to PLIANT THERAPEUTICS, INC.

Track Activities on PLRX

Account